Frequency of CHEK2 mutations in a population based, case-control study of breast cancer in young women.

Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.

A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer.

The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.

Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts.

Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility.

CHEK2 1100delC is not a risk factor for male breast cancer population.

Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.

BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases.

CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.

German populations with infrequent CHEK2*1100delC and minor associations with early-onset and familial breast cancer.

Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant.

Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer.

The CHEK2*1100delC allelic variant and risk of breast cancer: screening results from the Breast Cancer Family Registry.

CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies.